

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAREPTA THERAPEUTICS, INC.,
Petitioner,

v.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,
Patent Owner

and

REGENXBIO INC.,
Exclusive Licensee.

Case IPR2024-00580
Patent 11,680,274 B2

PATENT OWNERS' UPDATED EXHIBIT LIST

EXHIBITS

- EX2001 Roman Gardlík et al., *Vectors and Delivery Systems in Gene Therapy*, 11(4): Med. Sci. Monitor RA110 (2005)
- EX2002 Terence R. Flotte, *Gene Therapy: The First Two Decades and the Current State-of-the-Art*, 213(2): J. Cellular Physiology 301 (Nov. 2007)
- EX2003 Guangping Gao et al., *Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues*, 78(12): J. Virology 6381 (June 2004).
- EX2004 Guang-Ping Gao et al., *Novel Adeno-Associated Viruses from Rhesus Monkeys as Vectors for Human Gene Therapy*, 99(18): Proc. Nat'l Acad. Scis. 11854 (Sept. 2002)
- EX2005 C.J. Leonard & Kenneth I. Berns, *Adeno-Associated Virus Type 2: A Latent Life Cycle*, 48 Prog. Nucleic Acid Res. & Molecular Bio. 29 (1994)
- EX2006 Joshua C. Grieger & Richard J. Samulski, *Adeno-Associated Virus as a Gene Therapy Vector: Vector Development, Production and Clinical Applications*, 99 Adv. Biochem. Eng'g/Biotech. 119 (Oct. 2005)

- EX2007 Ekaterina Minskaia et al., *Viral Vectors in Gene Replacement Therapy*, 88(12-13): Biochem. (Moscow) 2157 (2023)
- EX2008 Alejandra E. Arbetman et al., *Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties*, 79(24): J. Virology 15238 (Dec. 2005)
- EX2009 Dawn E. Bowles et al., *Marker Rescue of Adeno-Associated Virus (AAV) Capsid Mutants: A Novel Approach for Chimeric AAV Production*, 77(1): J. Virology 423 (Jan. 2003)
- EX2010 Pierce J. Ogden et al., *Comprehensive AAV Capsid Fitness Landscape Reveals a Viral Gene and Enables Machine-Guided Design*, 366 Sci. 1139 (Nov. 2019)
- EX2011 Derek J. Blake et al., *Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle*, 82 Physio. Revs. 291 (2002)
- EX2012 Joshua C. Grieger & Richard J. Samulski, *Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps*, 79(15) J. Virology 9933 (Aug. 2005)
- EX2013 Hengjun Chao et al., *Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors*, 2(6) Molecular Therapy 619 (Dec. 2000)

- EX2014 United States Patent No. 7,282,199 to Gao et al.
- EX2015 United States Patent No. 7,198,951 to Gao et al.
- EX2016 Summary of Figures 2 and 4 in EX1008
- EX2017 Philip Cohen, *The Origins of Protein Phosphorylation*, 4 Nature Cell Bio. E127 (May 2002)
- EX2018 Makoto Uchino et al., *Dystrophin and Dystrophin-Related Protein in the Central Nervous System of Normal Controls and Duchenne Muscular Dystrophy*, 87 Acta Neuropathol. 129 (1994).
- EX2019 Mario Mietzsch et al., *Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8*, 94(6) J. Virology 6 (March 2020)
- EX2020 Clustal Omega Sequence Alignment of rh46, rh2, rh4, rh14, rh24, rh12, rh18, bb2, bb1, rh25, rh20, rh9, rh10, and rh11
- EX2021 Declaration of Dr. Casey M. Kraning in support of Motion for *Pro Hac Vice* Admission
- EX2022 Declaration of Deanna J. Reichel in support of Motion for *Pro Hac Vice* Admission
- EX2023 Melissa Bartel et al., *Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity*, 2 Front. Microbiol. 204 (Oct. 2011)

- EX2024 Jae-Hyung Jang et al., *Library Selection and Directed Evolution Approaches to Engineering Targeted Viral Vectors*, 98 Biotechnol. Bioeng. 3 (Oct. 2007)
- EX2025 David Schaffer, *AAV Shuffles to the Liver: Commentary on Lisowski et al.*, 1 Mol. Ther. Methods Clin. Dev. 14006 (2014)
- EX2026 David Ojala, *Adeno-Associated Virus Vectors and Neurological Gene Therapy*, Neuroscientist (2014)
- EX2027 Declaration of Dr. Richard Jude Samulski
- EX2028 Dr. Richard Jude Samulski's *Curriculum Vitae*
- EX2029 Chengwen Li and R. Jude Samulski, *Engineering adeno-associated virus vectors for gene therapy*, 21 Nat. Rev. 255 (April 2020)
- EX2030 Deposition Transcript of Dr. David Schaffer
- EX2031 Essential Amino Acids: Chart, Abbreviations and Structure
- EX2032 Sequence Alignments for AAVrh10, AAV7, AAV8, AAV1, AAV2, and AAV3
- EX2033 Michael Lochrie et al., *Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Affect Transduction and Neutralization*, 80:2 J. Virol. 821 (Jan. 2006)

- EX2034 Shaun Opie et al., *Identification of Amino Acid Residues in the Capsid Proteins of Adeno-Associated Virus Type 2 That Contribute to Heparan Sulfate Proteoglycan Binding*, 77:12 J. Virol. 6995 (June 2003)
- EX2035 Xun Zhou et al., *Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion, and Enhanced Transgene Expression*, 19 Int. J. Nanomedicine 7691 (July 2024)
- EX2036 Ziyu Jiang and Paul Dalby, *Challenges in scaling up AAV-based gene therapy manufacturing*, 41:10 Trends Biotechnol. 1268 (Oct. 2023)
- EX2037 Barath Jagadisan and Anil Dhawan, *Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy*, 22 Curr. Hepat. Rep. 276 (2023)
- EX2038 Dominique Larrey et al., *Drug-induced liver injury related to gene therapy: A new challenge to be managed*, 44 Liver Int. 3121 (2024)
- EX2039 Gemma Conroy, *How viruses are driving the gene-therapy renaissance*, 612 Nature S24 (Dec. 2022)
- EX2040 Eric Hoffman, *The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene*, 287 FEBS J. 3879 (2020)

- EX2041 Quan Gao and Elizabeth McNally, *The Dystrophin Complex: structure, function and implications for therapy*, 5(3) Compr. Physiol. 1223 (July 2015)
- EX2042 Fengqi Jiang et al., *Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022)*, Front. Cell. Infect. Microbiol. (2023)
- EX2043 A Gene Therapy Pioneer: The Jude Samulski Story website printout, <https://www.askbio.com/the-jude-samulski-story/>, last accessed Dec. 5, 2024
- EX2044 Errata Sheet of Dr. Jude Samulski Deposition on March 6, 2025, *Sarepta Therapeutics, Inc. v. The Trustees of the University of Pennsylvania and REGENXBIO Inc.*, Case No. IPR2024-00580
- EX2045 May 22, 2025 Demonstrative Slides for Oral Argument, *Sarepta Therapeutics, Inc. v. The Trustees of the University of Pennsylvania and REGENXBIO Inc.*, Case No. IPR2024-00580

Respectfully submitted,

Date: May 22, 2025

/Casey M. Kraning/

Susan E. Morrison, Reg. No. 56,332
Casey M. Kraning (Pro Hac Vice)
Deanna J. Reichel (Pro Hac Vice)

Fish & Richardson P.C.
60 South Sixth Street, Suite 3200
Minneapolis, MN 55402

Attorneys for REGENXBIO Inc.

Date: May 22, 2025

/Julie S. Goldemberg/

Dion M. Bregman, Reg. No. 45,645
MORGAN, LEWIS & BOCKIUS LLP
1400 Page Mill Rd., Palo Alto, CA
94304

Julie S. Goldemberg, Reg. No. 72,222
MORGAN LEWIS BOCKIUS LLP
1701 Market Street, Philadelphia, PA
19103-3007

*Attorneys for The Trustees of the
University of Pennsylvania.*

CERTIFICATE OF SERVICE

Pursuant to 37 CFR §§ 42.6(e), the undersigned certifies that on May 22, 2025, a complete and entire copy of this Patent Owners' Updated Exhibit List and the Demonstrative Slides as an exhibit are provided via email to the Petitioner by serving the email correspondence addresses of record as follows:

Quinn Emanuel Urquhart & Sullivan, LLP
51 Madison Avenue, 22nd Floor
New York, New York 10010
Robert Wilson, Reg. No. 45,227
robertwilson@quinnemanuel.com
Anne Toker, Reg. No. 53,692
annetoker@quinnemanuel.com
James Glass, Reg. No. 46,729
jimglass@quinnemanuel.com
Tel.: 212-849-7000

/Li Feng/

Li Feng

Fish & Richardson P.C.

60 South Sixth Street, Suite 3200

Minneapolis, MN 55402

lfeng@fr.com